US-based graphene transistor technology developer Cardea Bio has added $6.5m to a series A round featuring laboratory instrument producer Agilent Technologies now sized at more than $20m.
Healthcare-focused investment fund 3E Bioventures Capital led the $6.5m tranche, participating alongside undisclosed existing investors
Founded in 2013, Cardea Bio has developed graphene-based transistor technology which can integrate biology into electronics for purposes such as DNA testing, viral detection and molecular analysis.
The company received $7.8m in a March 2019 series A-1 round led by Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, that also featured Serra Ventures.
Six months later, Cardea Bio raised $7.5m in series A2 funding from Agilent, Tsingyuan Ventures, Lifespan Investments, Serra Ventures, Table Mountain Capital, Photon Fund and Taihill Venture. It had previously pulled in $1.1m from undisclosed investors in 2015, according to a regulatory filing.